Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients

E. Bajetta, N. Zilembo, M. Dowsett, L. Guillevin, A. Di Leo, L. Celio, A. Martinetti, A. Marchianò, P. Pozzi, S. Stani, E. Bichisao

Research output: Contribution to journalArticle

Abstract

Letrozole is an orally competitive aromatase inhibitor. This double- blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen. The pharmacokinetics of letrozole was also assessed. 46 patients entered the trial, 22 on letrozole 0.5 mg and 24 on 2.5 mg. A significant suppression of oestrone and oestradiol levels was achieved by both letrozole doses. Neither letrozole dose induced any changes in cortisol and aldosterone production at rest or after Synacthen stimulation. Androstenedione, testosterone, 17α-OH progesterone, triiodothyronine (T3) thyroxine, (T4) and thyroid-stimulating hormone (TSH) plasma levels did not show any significant changes. Sex hormone binding globulin (SHBG), follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels increased significantly over time. Plasma letrozole concentrations increased until reaching steady-state values after 1 month at the dose of 0.5 mg and after 2 months at 2.5 mg. In conclusion, both letrozole doses suppressed oestrogen levels without affecting adrenal activity.

Original languageEnglish
Pages (from-to)208-213
Number of pages6
JournalEuropean Journal of Cancer
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 1999

Fingerprint

letrozole
Multicenter Studies
Breast Neoplasms
Thyroxine
Sex Hormone-Binding Globulin
Aromatase Inhibitors
Androstenedione
Estrone
Follicle Stimulating Hormone
Triiodothyronine
Thyrotropin
Tamoxifen
Luteinizing Hormone
Aldosterone

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Letrozole
  • Oestrogens
  • Synacthen test

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. / Bajetta, E.; Zilembo, N.; Dowsett, M.; Guillevin, L.; Di Leo, A.; Celio, L.; Martinetti, A.; Marchianò, A.; Pozzi, P.; Stani, S.; Bichisao, E.

In: European Journal of Cancer, Vol. 35, No. 2, 02.1999, p. 208-213.

Research output: Contribution to journalArticle

@article{89f261a7a9ed451e9d1145a469a2e643,
title = "Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients",
abstract = "Letrozole is an orally competitive aromatase inhibitor. This double- blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen. The pharmacokinetics of letrozole was also assessed. 46 patients entered the trial, 22 on letrozole 0.5 mg and 24 on 2.5 mg. A significant suppression of oestrone and oestradiol levels was achieved by both letrozole doses. Neither letrozole dose induced any changes in cortisol and aldosterone production at rest or after Synacthen stimulation. Androstenedione, testosterone, 17α-OH progesterone, triiodothyronine (T3) thyroxine, (T4) and thyroid-stimulating hormone (TSH) plasma levels did not show any significant changes. Sex hormone binding globulin (SHBG), follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels increased significantly over time. Plasma letrozole concentrations increased until reaching steady-state values after 1 month at the dose of 0.5 mg and after 2 months at 2.5 mg. In conclusion, both letrozole doses suppressed oestrogen levels without affecting adrenal activity.",
keywords = "Aromatase inhibitors, Breast cancer, Letrozole, Oestrogens, Synacthen test",
author = "E. Bajetta and N. Zilembo and M. Dowsett and L. Guillevin and {Di Leo}, A. and L. Celio and A. Martinetti and A. Marchian{\`o} and P. Pozzi and S. Stani and E. Bichisao",
year = "1999",
month = "2",
doi = "10.1016/S0959-8049(98)00392-X",
language = "English",
volume = "35",
pages = "208--213",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "2",

}

TY - JOUR

T1 - Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients

AU - Bajetta, E.

AU - Zilembo, N.

AU - Dowsett, M.

AU - Guillevin, L.

AU - Di Leo, A.

AU - Celio, L.

AU - Martinetti, A.

AU - Marchianò, A.

AU - Pozzi, P.

AU - Stani, S.

AU - Bichisao, E.

PY - 1999/2

Y1 - 1999/2

N2 - Letrozole is an orally competitive aromatase inhibitor. This double- blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen. The pharmacokinetics of letrozole was also assessed. 46 patients entered the trial, 22 on letrozole 0.5 mg and 24 on 2.5 mg. A significant suppression of oestrone and oestradiol levels was achieved by both letrozole doses. Neither letrozole dose induced any changes in cortisol and aldosterone production at rest or after Synacthen stimulation. Androstenedione, testosterone, 17α-OH progesterone, triiodothyronine (T3) thyroxine, (T4) and thyroid-stimulating hormone (TSH) plasma levels did not show any significant changes. Sex hormone binding globulin (SHBG), follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels increased significantly over time. Plasma letrozole concentrations increased until reaching steady-state values after 1 month at the dose of 0.5 mg and after 2 months at 2.5 mg. In conclusion, both letrozole doses suppressed oestrogen levels without affecting adrenal activity.

AB - Letrozole is an orally competitive aromatase inhibitor. This double- blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast cancer patients progressing after tamoxifen. The pharmacokinetics of letrozole was also assessed. 46 patients entered the trial, 22 on letrozole 0.5 mg and 24 on 2.5 mg. A significant suppression of oestrone and oestradiol levels was achieved by both letrozole doses. Neither letrozole dose induced any changes in cortisol and aldosterone production at rest or after Synacthen stimulation. Androstenedione, testosterone, 17α-OH progesterone, triiodothyronine (T3) thyroxine, (T4) and thyroid-stimulating hormone (TSH) plasma levels did not show any significant changes. Sex hormone binding globulin (SHBG), follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels increased significantly over time. Plasma letrozole concentrations increased until reaching steady-state values after 1 month at the dose of 0.5 mg and after 2 months at 2.5 mg. In conclusion, both letrozole doses suppressed oestrogen levels without affecting adrenal activity.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Letrozole

KW - Oestrogens

KW - Synacthen test

UR - http://www.scopus.com/inward/record.url?scp=0033082373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033082373&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00392-X

DO - 10.1016/S0959-8049(98)00392-X

M3 - Article

C2 - 10448261

AN - SCOPUS:0033082373

VL - 35

SP - 208

EP - 213

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 2

ER -